Literature DB >> 6158884

Combined modality therapy for advanced head and neck cancer.

A Weaver, J J Loh, H Vandenberg, W Powers, S Fleming, R Mathog, M Al-Sarraf.   

Abstract

Seventy-five patients with stage III and IV squamous cell cancer of the head and neck, previously untreated, had two courses of chemotherapy with cis-platinum, Oncovin and bleomycin, followed by radical surgery, radiotherapy or both. Response to chemotherapy (complete and partial) was high (80 percent). In 36 patients radical surgery became possible. The overall survival improved statistically in patients who achieved complete or partial response to chemotherapy compared with those who had minimal or no response. Patients with well to moderately well differentiated cancer, or stage III disease, had a statistically better prognosis than patients with poorly differentiated cancer, or stage IV disease.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6158884     DOI: 10.1016/0002-9610(80)90209-3

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  3 in total

1.  Update in cancer chemotherapy: head and neck cancer, Part 2.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1986-11       Impact factor: 1.798

2.  The prognostic influence of induction chemotherapy on advanced head and neck carcinoma.

Authors:  H Picker; N Zingerle; K Böheim; A Lochs; H Spoendlin
Journal:  Arch Otorhinolaryngol       Date:  1986

3.  Analysis of DNA methylation associates the cystine-glutamate antiporter SLC7A11 with risk of Parkinson's disease.

Authors:  George D Mellick; Peter M Visscher; Jacob Gratten; Costanza L Vallerga; Futao Zhang; Javed Fowdar; Allan F McRae; Ting Qi; Marta F Nabais; Qian Zhang; Irfahan Kassam; Anjali K Henders; Leanne Wallace; Grant Montgomery; Yu-Hsuan Chuang; Steve Horvath; Beate Ritz; Glenda Halliday; Ian Hickie; John B Kwok; John Pearson; Toni Pitcher; Martin Kennedy; Steven R Bentley; Peter A Silburn; Jian Yang; Naomi R Wray; Simon J G Lewis; Tim Anderson; John Dalrymple-Alford
Journal:  Nat Commun       Date:  2020-03-06       Impact factor: 14.919

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.